The inhibition of MAX and MYCBP was of particular relevance because they have previously been proposed to play a pathogenic role in CTCL due to their effect on the C-Myc oncogene [19, 64, 65]. The gene discussed is MAX; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.